XXXX -125 implants versus external beam therapy for stages A2, B, and @entity263 .

@entity1 @entity1496 @entity263 @entity5
From 1974 to 1984, 307 @entity1 with @entity263 (Stage A2, B, or C) were referred to the Hunter Radiation Therapy Center, Yale-New Haven Hospital for definitive radiation therapy. One hundred forty-one @entity1 underwent an interstitial @entity1496 -125 implant (IMP) and 166 @entity1 received external beam irradiation (EB). For IMP @entity1 with Stage A2, B, and @entity5 , the actuarial 5-year disease-free survival (NED) rates were 88%, 84%, and 38% and the 9-year NED survival rates were 88%, 62%, and 30%, respectively. For EB @entity1 with Stage A2, B, and @entity5 , the 5-year NED survival rates were 88%, 77%, and 43% and the 9-year NED survival rates were 74%, 63%, and 37%, respectively. The NED survival rates by histologic grade were equivalent for the IMP and EB @entity1 . The absolute local control rate (LCR) was 77% for all of the IMP @entity1 but if one excludes @entity1 who were inadequately treated, the LCR was 82%. LCR in the EB @entity1 was 86%. The LCR for Stage A2, B, and C @entity1 treated with EB was 100%, 94%, and 82%, respectively. The LCR for Stage A2, B, and C @entity1 treated with an adequate IMP was 100%, 83%, and 71%, respectively. The complication rate was 8.5% in the IMP @entity1 (with 0% severe complications) and 14% in the EB @entity1 (with 3% severe complications). Our results indicate that a carefully selected group of IMP @entity1 (Stage A2, B) will have an equivalent NED survival rate and an excellent LCR compared to EB @entity1 but with fewer and less severe side effects.
